INS and diabetes mellitus: Among participants with diabetes, saroglitazar had significant effect on mean treatment differences in change from baseline in C-peptide (25.8% [95% CI: 11.3%], 40.3%), FPG (17.5% [95% CI: 4.9%, 30.1%], P = 0.008), HbA1c (8.9% [95% CI: 1%, 16.8%], P = 0.029), and insulin levels (41.0% [95% CI: 5.2%, 76.7%], P = 0.026) at week 12 when compared with fenofibrate (Fig. 3).